Skip to main content
. 2016 Jun 15;11(6):e0156747. doi: 10.1371/journal.pone.0156747

Table 3. Morbidity and mortality parameters measured in animals subjected to four separate challenge experiments (Exp.1, 2, 3 and 4)*.

Parameters Group I (n = 10) Group II (n = 10) Group III (n = 10)
Exp. 1 Exp. 2 Exp.3 Exp. 4 Exp. 1 Exp. 2 Exp.3 Exp. 4 Exp. 1 Exp. 2 Exp.3 Exp. 4
Morbidity (%) 100 100 100 100 100 100 100 100 100 100 100 100
Mean duration for clinical onset (days) (range) 2.7(1–5) 4.2(1–6) 3 (1–5) 3.4(2–4) 3.1(2–4) 3.4(2–5) 3(2–5) 2.9(2–4) 1.1(1–3) 1.2(1–2) 1.3(1–2) 1.5(1–2)
Overall mean patent period (days) (range) 10.1(7–12) 6(6–12) 10.1(8–12) 10.1(9–12) 7(5–8) 9.2(4–12) 9.7(6–13) 9.2(7–12) 7 6 8.76–13) 11.3(9–13)
Mean patent period (days) for birds that died (range) 7 7.5(7–8) 11(9–13) 12 7(6–8) 5.3(4–6) 8 12 7 6 8.7(5–13) 11.3(9–13)
Mean patent period (in days) for birds that survived (range) 10.9(10–12) 5.6(4–8) 9.9(9–11) 9.9(9–11) 7(5–8) 10.9(9–12) 10.1(8–12) 8.9(7–12) NA NA NA NA
Mortality (%) 20 20 10 10 50 30 20 10 100 100 100 100
Total no. sick birds but recovered (%) 80 80 90 90 50 70 80 90 0 0 0 0
Case fatality rate (%) 20 20 10 10 50 30 20 10 100 100 100 100
Mean death time (MDT) 8 12 14 14 7.8 9.3 10 14 8.2 8 9.8 12.8
Protection (%) 80 80 90 90 50 70 80 90 0 0 0 0

*Experiments 1, 2, 3 and 4 were carried out on birds of 21, 28 and 35 and 42 days of age. In both cases, Group 1 (vaccinated with rHVT-H5 vaccine at 1 day old), Group II (vaccinated with inactivated KV-H5 vaccine at 8 days old), Group III (unvaccinated control). All birds were challenged with HPAI H5N1 virus (A/Chicken/Egypt/128S/2012 (H5N1)) (GeneBank Accession No. JQ858485) via the oculo-nasal route with 100 μl (50_ul in eye, 50_ul in nose) of inoculum containing 106 EID50 per duck.